Meghana Keshavan from STAT News - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting		More beef in the gene editing space - 1 day ago Versant enters obesity with new startup - 2 days ago A win for Apellis, a setback for Astellas - 4 days ago Risk of aspiration during surgery added to GLP-1 drug labels - 12 days ago The biotech news roundup to start your week - 19 days ago A setback for the tau approach to Alzheimer’s - 22 days ago The biotech news you need to read today - 26 days ago STAT+: Potential competition for RSV prophylactic Beyfortus - about 1 month ago Eli Lilly releases new data on weekly insulin - 2 months ago Lilly has more positive data on its weekly insulin - 3 months ago STAT+: Rick Doblin, ‘unleashed,’ blasts FDA over Lykos drug rejection and turns to global push for MDMA therapy - 3 months ago Is pharma still fearful of the Inflation Reduction Act? - 3 months ago STAT+: Lykos Therapeutics cuts 75% of staff after FDA rejects MDMA-assisted therapy - 3 months ago A tough week for MDMA-assisted psychotherapy - 3 months ago STAT+: Three MDMA therapy papers retracted over data integrity concerns - 3 months ago FDA rejects MDMA as a psychedelic treatment for PTSD - 4 months ago STAT+: Why did Novo pull heart failure paperwork for Wegovy? - 4 months ago Element Biosciences raises another massive round - 4 months ago The biotech news you missed this week - 5 months ago Will Medicare finally begin covering weight loss drugs like Zepbound and Wegovy? - 5 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 6 months ago ICER casts doubt on Sarepta’s DMD gene therapy - 7 months ago The latest updates on cancer research from the weekend - 8 months ago Sanofi resolves most Zantac litigation - 8 months ago How resurrecting extinct species might impact medicine - 8 months ago New data on liquid biopsy for colorectal cancer detection still underwhelms - 8 months ago Lawmakers want to add more Chinese biotechs to defense list - 8 months ago How GLP-1’s moved from research labs to national TV - 8 months ago How will the Supreme Court’s mifepristone decision impact biopharma? - 8 months ago EU adviser says Illumina merger was not problematic - 8 months ago What happens when an approved drug doesn’t work? - 8 months ago Eli Lilly’s anti-vanity ad campaign for Oscars - 9 months ago Serum Institute of India wants government HPV contract - 9 months ago Despite good data, Ironwood’s shares plummet - 9 months ago What do CEOs owe the world? - 9 months ago Replicate’s srRNA rabies vaccine effective in Phase 1 - 9 months ago The need to know biotech news stories today - 9 months ago Psychedelic investment continues to ramp up - 10 months ago Does Moderna’s RSV vaccine lose efficacy faster than others? - 10 months ago Regeneron is interested in obesity treatments that combat muscle loss - 10 months ago 23andMe breach targeted Chinese, Jewish populations - 10 months ago The Senate health committee looks into its first subpoena in 40 years - 10 months ago Novartis reportedly decides to pass on Cytokinetics - 11 months ago Why did Allogene cancel two clinical trials for its off-the-shelf cell therapy? - 11 months ago Inhaled vaccines could stop Covid infections, monkey studies show - 11 months ago The biotech updates you need to read today - 11 months ago The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive - 11 months ago FDA chastens pet companies over antibiotics - 11 months ago The biotech news you missed from the weekend - 12 months ago CRISPR is about to make history. Here’s the 5-minute rundown of what to expect - 12 months ago
2	Olivia Goldhill STAT News		FDA rejects MDMA as a psychedelic treatment for PTSD - 4 months ago